Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 29 2021 - 8:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of January 2021
Commission
File Number: 001-37353
BIONDVAX
PHARMACEUTICALS LTD.
(Translation
of registrant’s name into English)
Jerusalem
BioPark, 2nd Floor
Hadassah
Ein Kerem Campus
Jeusalem,
Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
On
January 29, 2021, BiondVax Pharmaceuticals Ltd. announced the pricing of $12.1 million follow-on underwritten offering of American
Depositary Shares.
Exhibit
Index
Exhibit
99.1 is hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration No. 333-240189) and
its Registration Statement on Form S-8 (Registration No. 333-239344).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax
Pharmaceuticals Ltd.
|
|
|
|
Date:
January 29, 2021
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron
Babecoff
|
|
|
Chief
Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024